非布索坦怎么用？

Gout is a common rheumatic disease, and its onset is directly related to an increase in blood uric acid. It is a recurring inflammatory disease caused by an increase in uric acid in the blood due to excessive production of uric acid or poor excretion of uric acid, and the deposition of urate crystals in the joint synovium, bursa, cartilage and other tissues. Currently, the drug of choice for the treatment of gout is. So, how to use febuxostat?

How to use febuxostat: Generally, start with 10 mg (one tablet) per day, take it orally once a day, and after 6 weeks, 40 mg once a day. After that, you can gradually increase the dosage while confirming the uric acid value in the blood.

Serum uric acid can be retested after 2 weeks of treatment with febuxol. The treatment goal is to reduce and maintain serum uric acid levels below 6 mg/dl. The drug effect is generally maintained at 40 mg once a day, and can be increased or decreased appropriately according to the patient's condition. The maximum dosage is 60 mg a day.

Food and antacid effects do not need to be considered when administering febuxostat.

Febuxostat can quickly reduce blood uric acid levels, and in the early stages of medication, the probability of causing an acute gout attack is greater than that of allopurinol. Therefore, the recommended initial dose of febuxostat is 20 to 40 mg once daily.

To prevent gout attacks during the initial stages of taking febuxostat, it is recommended to take NSAIDs or colchicine at the same time. Preventive treatment is maintained for 3 to 6 months, and is adjusted according to the patient's gouty arthritis attack.

If gout attacks during treatment with febuxostat, there is no need to stop taking the medicine.

Regarding use by special groups:

Patients with hepatic insufficiency: Patients with mild or moderate hepatic insufficiency do not need to adjust the dosage. Patients with severe hepatic insufficiency should use febuxostat with caution.

Renal Impairment: No dose adjustment is required for patients with mild or moderate renal impairment. There are insufficient study data in patients with severe renal impairment and febuxostat should be used with caution in these patients.

Febuxostat is eliminated via hepatic and renal pathways. About 49% is excreted through urine and about 45% is excreted through feces. The average terminal elimination half-life is approximately 5 to 8 hours.